ME1 and prostate adenocarcinoma: Notably, ME1 methylation levels were significantly reduced in the tissues of patients with BLCA, cholangiocarcinoma (CHOL), COAD, esophageal carcinoma (ESCA), kidney renal papillary cell carcinoma (KIRP), LIHC, lung adenocarcinoma (LUAD), LUSC, and rectum adenocarcinoma (READ), whereas an increase in methylation levels was observed in kidney renal clear cell carcinoma (KIRC) and PRAD.